The Biorepository Core (BioC) complements the services provided by the Pharmacology Core and provides the laboratory-based, epidemiological, and clinical investigators with a diverse selecfion of human fissue specimens necessary for research. A major goal of the Core is to accelerate the transifion from basic science to clinical research by providing access to well characterized human tissue. Within the established rules ofthe Human Invesfigafive Committee and HIPAA, the Core performs several funcfions. These include patient consenfing, tissue collection, tissue processing, banking and storage, retrieval, and transfer of fresh frozen and formalin fixed paraffin embedded human tissue obtained from the surgical suites and endoscopic units of KCI. Key services include case identification by diagnostic categories and subsequent retrieval of pathology materials (reports, blocks, slides, banked fixed and frozen materials), providing complete and accurate pathological diagnosis and interpretafions.
; BioC services enable basic science, population science, and clinical researchers to expand further into translational research. This is accomplished by the Core providing unique malignant and benign focused tissues from its tissue bank. Additionally, KCI investigators are able to use the BioC to rapidly evaluate targets and biomarkers relevant to cancer cure. Tissues acquired through this Core come from a diverse population, aiding research into health disparities.
|Watza, Donovan; Purrington, Kristen S; Chen, Kang et al. (2017) Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis 9:4162-4164|
|Eggly, Susan; Hamel, Lauren M; Foster, Tanina S et al. (2017) Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists. Patient Educ Couns 100:818-826|
|Bao, Bin; Mitrea, Cristina; Wijesinghe, Priyanga et al. (2017) Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep 7:44125|
|Bernardo, Margarida M; Dzinic, Sijana H; Matta, Maria J et al. (2017) The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin. J Cell Biochem 118:1639-1647|
|Soave, Claire L; Guerin, Tracey; Liu, Jinbao et al. (2017) Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev 36:717-736|
|Jones, Carissa C; Bush, William S; Crawford, Dana C et al. (2017) Germline Genetic Variants and Lung Cancer Survival in African Americans. Cancer Epidemiol Biomarkers Prev 26:1288-1295|
|Bosnyák, Edit; Michelhaugh, Sharon K; Klinger, Neil V et al. (2017) Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. Clin Nucl Med 42:341-347|
|Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323|
|Tan, Zhijing; Nie, Song; McDermott, Sean P et al. (2017) Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line. J Proteome Res 16:842-851|
|Embogama, D Maheeka; Pflum, Mary Kay H (2017) K-BILDS: A Kinase Substrate Discovery Tool. Chembiochem 18:136-141|
Showing the most recent 10 out of 726 publications